CDK4 and neoplasm: The goal of the present investigation was to evaluate a highly sensitive tumor-informed ctDNA assay, with a test limit of detection (LoD95) of 0.001% variant allele frequency (VAF), in HR+/HER2− MBC patients receiving standard of care ET and CDK4/6i.